Supemtek® + Vaxigriptetra®
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Morbid Obesity
Conditions
Morbid Obesity, Severe Obesity
Trial Timeline
Nov 7, 2022 → Oct 3, 2023
NCT ID
NCT05409612About Supemtek® + Vaxigriptetra®
Supemtek® + Vaxigriptetra® is a phase 3 stage product being developed by Sanofi for Morbid Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT05409612. Target conditions include Morbid Obesity, Severe Obesity.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05409612 | Phase 3 | Completed |
Competing Products
7 competing products in Morbid Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Approved | 85 |
| Posaconazole Injection [Noxafil] 300mg + Posaconazole Injection [Noxafil] 400mg | Merck | Approved | 85 |
| Rocuronium | Merck | Approved | 85 |
| Placebo + IBI362 | Innovent Biologics | Phase 3 | 76 |
| Molindone | Supernus Pharmaceuticals | Phase 2 | 47 |
| SPN-810M | Supernus Pharmaceuticals | Phase 1 | 28 |
| SPN-810 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |